Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$3,947 Mln
P/E Ratio
--
P/B Ratio
1.19
Industry P/E
--
Debt to Equity
0.02
ROE
-0.2 %
ROCE
-19.97 %
Div. Yield
0 %
Book Value
27.1
EPS
-3.8
CFO
$-713.03 Mln
EBITDA
$-835.07 Mln
Net Profit
$-930.03 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Vaxcyte (PCVX)
| -61.81 | -58.13 | -64.55 | -48.61 | 10.45 | -- | -- |
|
BSE Sensex*
| 2.27 | 4.06 | 4.74 | 8.66 | 11.85 | 20.59 | 11.12 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Vaxcyte (PCVX)
| 30.07 | 30.97 | 101.56 | -10.46 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.48 | 9,808.03 | 20.22 | 23.13 | |
| 282.28 | 8,956.09 | 22.08 | 58.42 | |
| 25.74 | 9,559.25 | -- | -28.77 | |
| 101.74 | 10,030.35 | 30.81 | 14.16 |
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational... pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD). The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV being developed for the prevention of IPD in adults and children. VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI to prevent dysentery and shigellosis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. Address: 825 Industrial Road, San Carlos, CA, United States, 94070 Read more
Co-Founder, CEO & Director
Mr. Grant E. Pickering M.B.A.
Co-Founder, CEO & Director
Mr. Grant E. Pickering M.B.A.
Headquarters
San Carlos, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Vaxcyte Inc (PCVX) stood at $ 3,511 Mln as on 31-Dec-24
The share price of Vaxcyte Inc (PCVX) is $31.26 (NASDAQ) as of 22-Apr-2025 16:00 EDT. Vaxcyte Inc (PCVX) has given a return of 10.45% in the last 3 years.
Vaxcyte Inc (PCVX) has a market capitalisation of $ 3,947 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Vaxcyte Inc (PCVX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Vaxcyte Inc (PCVX) and enter the required number of quantities and click on buy to purchase the shares of Vaxcyte Inc (PCVX).
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD). The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV being developed for the prevention of IPD in adults and children. VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI to prevent dysentery and shigellosis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. Address: 825 Industrial Road, San Carlos, CA, United States, 94070
The CEO & director of Mr. Grant E. Pickering M.B.A.. is Vaxcyte Inc (PCVX), and CFO & Sr. VP is Mr. Grant E. Pickering M.B.A..
There is no promoter pledging in Vaxcyte Inc (PCVX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Vaxcyte Inc. (PCVX) | Ratios |
|---|---|
|
Return on equity(%)
|
-20.41
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Vaxcyte Inc (PCVX) was $-464 Mln.
$0.87
(
